GlaxoSmithKline (GSK) and Vir Biotechnology have announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorisation (EUA) for VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and older weighing at least 40… Read More
Mogrify, a UK company which aims to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards 2020. Read More
Biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, has launched after closing its $22 million Series A funding round. 1910 Genetics’ aim is to decrease the timeline and cost of drug development, while improving the success rate of getting medicines to patients. 1910 Genetics… Read More
Novadiscovery (NOVA), a health tech company offering JINKO, a clinical trial simulation platform to predict drug efficacy and optimise clinical trial development, has announced its new collaboration with Takeda Pharmaceutical. This is aimed at incorporating clinical simulation technology on virtual patients into Takeda France’s access strategy and building on an… Read More
Turnover at pharmaceutical and biotech product development consultancy Boyds has surged by 25% as demand for its specialist services continues to grow. The company has added seven regulatory and medical affairs experts to its team, and is now launching an even larger recruitment drive creating up to ten new roles… Read More
Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains. The COV-X program targets a protein which is essential for viral replication across a broad spectrum of related coronaviruses, including SARS-CoV-1, MERS-CoV and SARS-CoV-2. If successfully developed, the treatment aims to form… Read More
SignalChem Lifesciences, a clinical-stage company who develop novel targeted therapies for oncology, has announced its collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC). AXL,… Read More
IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, an emerging leader in AI-enabled drug design, have announced a collaboration focused on the discovery of novel drug candidates for… Read More
The Catalogue of Somatic Mutations in Cancer (COSMIC), based at the Wellcome Sanger Institute, has launched a new feature that will allow users to see which drugs are available to target specific cancer mutations. This new resource is a positive step towards making precision oncology possible for all cancer patients. Read More
A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The findings, which include studies in cell lines and animal models, appeared in JCI Insight and focus on a protein called CD6 as… Read More
Scientists from MIPT and ITMO University and their colleagues have studied the formation and growth of crystals from simple organic molecules into large associations, which may help create capsules for targeted drug delivery to specific tissues in the human body. The scientific paper was published in the journal Crystal Growth… Read More
Researchers in the Abramson Cancer Center at the University of Pennsylvania have published a new preclinical study which found hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease. The study, published online in Cell Press’s iScience, showed how two… Read More
Clinical stage gene therapy company, Ilya Pharma, has released further results from the first in human (FIH) trial of ILP100 for treating difficult and chronic wounds. ILP100 represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the wound site. After delivery, ILP100 enhances the healing properties of immune cells in the… Read More
The Data and Safety Monitoring Board (DSMB) has notified the National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority (BARDA), and AstraZeneca that it is “concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial”. Trial volunteers received two standard… Read More
New research from scientists at the Wellcome Sanger Institute has shown a gene not previously linked to cancer plays a key role in the spread of certain cancers to the lungs. The team found that when the gene LRRN4CL was over-expressed in mice, the… Read More
Phesi, provider of AI-powered clinical development analytics products and solutions, and Accenture, a services and consulting company, have released the first of a series of reports exploring the use of synthetic data in clinical development. In recent years, the volume of data created through clinical trials and electronic patient records… Read More
